journal
Journals American Society of Clinical O...

American Society of Clinical Oncology Educational Book

https://read.qxmd.com/read/38207251/update-on-biomarkers-in-renal-cell-carcinoma
#1
JOURNAL ARTICLE
Renée M Saliby, Eddy Saad, Soki Kashima, David A Schoenfeld, David A Braun
Immune checkpoint inhibitors have significantly transformed the treatment paradigm for metastatic renal cell carcinoma (RCC), offering prolonged overall survival and achieving remarkable deep and durable responses. However, given the multiple ICI-containing, standard-of-care regimens approved for RCC, identifying biomarkers that predict therapeutic response and resistance is of critical importance. Although tumor-intrinsic features such as pathological characteristics, genomic alterations, and transcriptional signatures have been extensively investigated, they have yet to provide definitive, robust predictive biomarkers...
January 2024: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/38206291/de-escalation-of-therapy-for-prostate-cancer
#2
JOURNAL ARTICLE
Tarik Esen, Baris Esen, Kosj Yamaoh, Ugur Selek, Derya Tilki
Prostate cancer (PCa) is the second most commonly diagnosed cancer in men with around 1.4 million new cases every year. In patients with localized disease, management options include active surveillance (AS), radical prostatectomy (RP; with or without pelvic lymph node dissection), or radiotherapy to the prostate (with or without pelvic irradiation) with or without hormonotherapy. In advanced disease, treatment options include systemic treatment(s) and/or treatment to primary tumour and/or metastasis-directed therapies (MDTs)...
January 2024: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/38206274/immuno-oncology-advances-in-genitourinary-cancers
#3
REVIEW
Peter D Zang, Arkhjamil Angeles, Tanya B Dorff, Sumanta K Pal, Shilpa Gupta
Immuno-oncology (IO) has made monumental gains in the past decade in the genitourinary space. In this review, we highlight advances with IO in renal cell carcinoma where it now has become standard-of-care frontline therapy in the metastatic setting but also discuss challenges with the initial approach. In urothelial carcinoma, we discuss the growing use of IO including exciting recent updates with IO-based regimens that may soon become the new standard of care. We further discuss difficulties with IO in prostate cancer, germ cell tumors, and penile squamous cell carcinoma...
January 2024: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/38190577/treatment-of-oligometastatic-gi-cancers
#4
REVIEW
Clayton T Marcinak, Patrick B Schwartz, Mustafa M Basree, Newton Hurst, Michael Bassetti, Jeremy D Kratz, Nataliya V Uboha
Oligometastatic state is believed to potentially represent a transitional stage between early, locoregional state disease and widely metastatic disease. Historically, locoregional approaches, particularly in advanced colorectal cancers, have demonstrated efficacy in select patients with limited burden of metastatic disease. Recent strides in systemic therapies, including biomarker-based treatments and immunotherapy, alongside innovations in surgical techniques and novel locoregional approaches such as stereotactic radiotherapy and ablation, have ushered in a new era of therapeutic possibilities across all oligometastatic GI cancers...
January 2024: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/38176691/emerging-insights-in-small-cell-carcinoma-of-the-genitourinary-tract-from-diagnosis-to-novel-therapeutic-horizons
#5
REVIEW
Ross S Liao, Hui Ting Ruan, Albert Jang, Melissa Huynh, Rosa Nadal Rios, Jean H Hoffman-Censits, Shuanzeng Wei, Omar Y Mian, Pedro C Barata
Small-cell carcinomas (SCCs) of the genitourinary (GU) tract are rare malignancies with high metastatic potential. The most common primary sites are the bladder and prostate, but case reports of primary SCC of the kidney, ureter, and urethra also exist. The majority of patients present with gross hematuria, irritative or obstructive urinary symptoms, and symptoms of locoregionally advanced or metastatic disease at initial presentation. SCC of the bladder presents with nodal or metastatic involvement in the majority of cases and requires the use of platinum-based chemotherapy in combination with surgery and/or radiation...
January 2024: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/38175973/updates-on-systemic-therapy-for-hepatocellular-carcinoma
#6
REVIEW
Panagiotis Ntellas, Ian Chau
This review explores the dynamic landscape of hepatocellular carcinoma (HCC) treatment, emphasizing on recent developments across various stages and therapeutic approaches. Although curative strategies such as hepatectomy and thermal ablation are standard for early-stage cases, high relapse rates drive investigations into adjuvant and perioperative treatment. Adjuvant therapies face hurdles, but noteworthy advances include IMbrave050 setting a new standard with atezolizumab/bevacizumab. Locoregional treatments gain significance, especially for multifocal HCC, with the integration of innovative combinations with systemic therapies, showing improved outcomes...
January 2024: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37713646/erratum-metastatic-hormone-sensitive-prostate-cancer-toward-an-era-of-adaptive-and-personalized-treatment
#7
(no author information available yet)
No abstract text is available yet for this article.
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37459578/immune-resistance-mechanisms-and-the-road-to-personalized-immunotherapy
#8
JOURNAL ARTICLE
Miles Piper, Harriet Kluger, Eytan Ruppin, Siwen Hu-Lieskovan
What does the future of cancer immunotherapy look like and how do we get there? Find out where we've been and where we're headed in A Report on Resistance: The Road to personalized immunotherapy.
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37437232/systemic-therapy-in-older-patients-with-high-risk-disease
#9
JOURNAL ARTICLE
Etienne G C Brain
Adjuvant systemic treatments for older patients with breast cancer require constant dose or schedule adjustments of standards established for younger ones. This is mainly due to frailty that increases according to age (40%-50% of signals in all comers after age 70 years) and remains difficult to spot or diagnose accurately and therefore is often overlooked. Older patients are at higher risk to develop side effects whether under chemotherapy, optimized endocrine treatment, or targeted therapies. Pharmacokinetic reflects poorly functional reserves that reduce with aging and is therefore misleading...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37433102/high-cost-of-chimeric-antigen-receptor-t-cells-challenges-and-solutions
#10
REVIEW
Edward R Scheffer Cliff, Amar H Kelkar, David A Russler-Germain, Frazer A Tessema, Adam J N Raymakers, William B Feldman, Aaron S Kesselheim
Chimeric antigen receptor (CAR) T-cells are a cellular immunotherapy with remarkable efficacy in treating multiple hematologic malignancies but they are associated with extremely high prices that are, for many countries, prohibitively expensive. As their use increases both for hematologic malignancies and other indications, and large numbers of new cellular therapies are developed, novel approaches will be needed both to reduce the cost of therapy, and to pay for them. We review the many factors that lead to the high cost of CAR T-cells and offer proposals for reform...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37390390/erratum-molecular-profiling-in-neuro-oncology-where-we-are-where-we-re-heading-and-how-we-ensure-everyone-can-come-along
#11
(no author information available yet)
No abstract text is available yet for this article.
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37390386/erratum-antibody-drug-conjugates-in-gynecologic-cancer
#12
(no author information available yet)
No abstract text is available yet for this article.
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37390382/erratum-state-of-the-art-multidisciplinary-management-of-oligometastatic-renal-cell-carcinoma
#13
(no author information available yet)
No abstract text is available yet for this article.
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37390373/aligning-germline-cancer-predisposition-with-tumor-based-next-generation-sequencing-for-modern-oncology-diagnosis-interception-and-therapeutic-development
#14
JOURNAL ARTICLE
Timothy A Yap, Zsofia K Stadler, Leigh Anne Stout, Bryan P Schneider
In the era of precision medicine, genomic interrogation for identification of both germline and somatic genetic alterations has become increasingly important. While such germline testing was usually undertaken via a phenotype-driven single-gene approach, with the advent of next-generation sequencing (NGS) technologies, the widespread utilization of multigene panels, often agnostic of cancer phenotype, has become a commonplace in many different cancer types. At the same time, somatic tumor testing in oncology performed for the purpose of guiding therapeutic decisions for targeted therapies has also rapidly expanded, recently starting to incorporate not just patients with recurrent or metastatic cancer but even patients with early-stage disease...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37384855/local-therapies-for-metastatic-sarcoma-why-when-and-how
#15
JOURNAL ARTICLE
Nadia Hindi, Nadia Laack, Kelvin Hong, Peter Hohenberger
Management of patients with advanced sarcoma has been evolving in recent decades, from a one-fit-all perspective to a more refined, personalized, and multidisciplinary approach. In parallel, the evolution of local therapies (radiotherapy, surgical and interventional radiology techniques) has contributed to the improvement of survival of patients with advanced sarcoma. In this article, we review the evidence regarding local treatments in advanced sarcoma, as well as its integration with systemic therapies, to provide the reader a wider and deeper perspective on the management of patients with metastatic sarcoma...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37364224/novel-immunotherapeutics-perspectives-on-checkpoints-bispecifics-and-vaccines-in-development
#16
JOURNAL ARTICLE
Firas Y Kreidieh, Hussein A Tawbi, Aikaterini Alexaki, Hossein Borghaei, Lana E Kandalaft
Over the past decade, the advent of molecular techniques and deeper understanding of the tumor microenvironment (TME) have enabled the development of a multitude of immunotherapy targets and approaches. Despite the revolutionary advancement in immunotherapy, treatment resistance remains a challenge leading to decreased response rate in a significant proportion of patients. As such, there has recently been an evolving focus to enhance efficacy, durability, and toxicity profiles of immunotherapy. Although immune checkpoint inhibitors have revolutionized cancer treatment with many already-approved antibodies and several others in the pipeline, bispecific antibodies build on their success in an attempt to deliver an even more potent immune response against tumor cells...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37339391/shared-decision-making-in-the-care-of-patients-with-cancer
#17
JOURNAL ARTICLE
Salma Shickh, Konstantinos Leventakos, Mark A Lewis, Yvonne Bombard, Victor M Montori
Shared decision making (SDM) is a method of care that is suitable for the care of patients with cancer. It involves a collaborative conversation seeking to respond sensibly to the problematic situation of the patient, cocreating a plan of care that makes sense intellectually, practically, and emotionally. Genetic testing to identify whether a patient has a hereditary cancer syndrome represents a prime example of the importance for SDM in oncology. SDM is important for genetic testing because not only results affect current cancer treatment, cancer surveillance, and care of relatives but also these tests generate both complex results and psychological concerns...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37335956/early-stage-triple-negative-breast-cancer-journey-beginning-end-and-everything-in-between
#18
REVIEW
Hyo Sook Han, Praveen Vikas, Ricardo L B Costa, Nusrat Jahan, Ammanuel Taye, Erica M Stringer-Reasor
Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early-stage breast cancer includes systemic chemotherapy and surgery, with or without radiation therapy. More recently, immunotherapy is approved to treat TNBC, but managing immune-rated adverse events while balancing efficacy is a challenge. The purpose of this review is to highlight the current treatment recommendations for early-stage TNBC and the management of immunotherapy toxicities...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37327467/not-too-little-not-too-much-optimizing-more-versus-less-locoregional-treatment-for-older-patients-with-breast-cancer
#19
JOURNAL ARTICLE
Jennifer Tseng, Jose G Bazan, Christina A Minami, Mara A Schonberg
Although undertreatment of older women with aggressive breast cancers has been a concern for years, there is increasing recognition that some older women are overtreated, receiving therapies unlikely to improve survival or reduce morbidity. De-escalation of surgery may include breast-conserving surgery over mastectomy for appropriate candidates and omitting or reducing extent of axillary surgery. Appropriate patients to de-escalate surgery are those with early-stage breast cancer, favorable tumor characteristics, are clinically node-negative, and who may have other major health issues...
June 2023: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/37319380/managing-a-long-and-winding-road-estrogen-receptor-positive-breast-cancer
#20
REVIEW
Michael Gnant, Nicholas C Turner, Cristina Hernando
We review key topics in the management of estrogen receptor (ER)-positive human epidermal growth factor receptor 2-negative breast cancer. The single biggest challenge in management of this disease is late relapse, and we review new methods for identifying which patients are at risk of late relapse and potential therapeutic approaches in clinical trials. CDK4/6 inhibitors have become a standard treatment option for high-risk patients in both the adjuvant setting and the first-line metastatic setting, and we review data on optimal treatment after progression on CDK4/6 inhibitors...
June 2023: American Society of Clinical Oncology Educational Book
journal
journal
46604
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.